07:00 , Oct 7, 2010 |  BC Innovations  |  Targets & Mechanisms

Getting to the essence of Staph

Two recent studies from The University of Chicago have identified vaccine candidates to prevent Staphylococcus aureus infection. 1,2 The researchers think their strategy of targeting essential surface-localized virulence factors could generate better results than current...
07:00 , Apr 10, 2008 |  BC Innovations  |  Targets & Mechanisms

Staph: The NOse Have It

A paper published in...
07:00 , Apr 16, 2007 |  BC Week In Review  |  Company News

FermaVir, Inhibitex deal

INHX will acquire FMVR in a stock-for-stock transaction. Each FMVR share will be exchanged for 0.55 shares of INHX stock, which values FMVR at about $19 million based on FMVR’s 20.8 million outstanding shares and...
07:00 , May 15, 2006 |  BC Week In Review  |  Clinical News

Aurexis: Phase I start

INHX will begin next quarter a U.S. Phase I study in 16 patients. Inhibitex Inc. (INHX), Atlanta, Ga.   Product: Aurexis   Business: Infectious   Molecular target: ClfA   Description: Humanized monoclonal antibody against ClfA...
07:00 , Apr 10, 2006 |  BioCentury  |  Finance

Ebb & Flow

Lion bioscience...
00:25 , Apr 4, 2006 |  BC Extra  |  Top Story

Inhibitex down on failed Phase III

On Monday, INHX fell $4.79 (66%) to $2.47 on 14.9 million shares after Veronate missed the primary endpoint of preventing hospital-acquired S. aureus infections in a Phase III trial in very low birth weight infants....
07:00 , May 16, 2005 |  BC Week In Review  |  Clinical News

Aurexis: Phase II data

In a double-blind, placebo-controlled, U.S. Phase II trial in 60 patients, Aurexis plus standard antibiotic therapy led to 1 death and 1 infection relapse vs. 4 deaths with antibiotic therapy plus placebo. The combination therapy...
07:00 , May 16, 2005 |  BioCentury  |  Finance

Ebb & Flow

The Bank of New York has seen a big increase in the number of ex-U.S. biotech companies seeking Level I ADRs in order to get access to U.S. investors. The move is most likely being...
07:00 , Apr 4, 2005 |  BioCentury  |  Finance

2Q milestones

2Q milestones...
08:00 , Jan 10, 2005 |  BC Week In Review  |  Clinical News

Aurexis: Phase II completed enrollment

INHX completed enrollment of 60 patients in a double-blind, placebo-controlled Phase II trial. Inhibitex Inc. (INHX), Atlanta, Ga.   Product: Aurexis   Business: Infectious   Molecular target: ClfA   Description: Humanized monoclonal antibody against ClfA...